Thermo Fisher Scientific

In this application note, we show the reproducibility of gene expression measurements from Well to Well on 384-well TaqMan Array Cards, and Gene Expression assay panels.

Real-time qPCR: an established genomic technology in the discovery & development of therapeutic monoclonal antibodies.

Developing and manufacturing biologics requires compliant technologies and methods that provide excellent accuracy, consistency, and quality control (QC) with continuous automation potential to ensure the best possible product is delivered in the right time frame. PCR methods that enable quantification of target nucleic acid sequences—namely quantitative real-time PCR (qPCR) and digital PCR (dPCR)—have become core technologies for delivering high-quality results in a range of applications throughout biologics development and biomanufacturing. qPCR and dPCR methods are the gold standards for sensitive, specific detection and quantification of nucleic acid targets, which are useful for QC testing a wide variety of biologic characteristics.

We effectively demonstrate that TaqPath BactoPure Microbial Detection Master Mix is ideally suited for applications in biopharmaceutical manufacturing. TaqPath BactoPure Microbial Detection Master Mix enables consistent and sensitive detection of relevant targets in biopharmaceutical cell samples.

The animal origin-free (AOF) trend in bioprocessing has taken a while to reach microbial bioproduction. In this podcast, we explore the reasons behind this and delve into how AOF products are impacting the future of biopharmaceutical manufacturing. We also discuss the first chemically defined microbial medium—the Gibco™ Bacto™ CD Supreme Fermentation Production Medium (FPM). Hydrolysate-free and AOF, this dry powder medium was specially designed to support high-cell-density cultures of E. Coli. Listen to bioprocessing experts and discover more.

This webinar highlights the development of the first chemically defined microbial medium. Designed to simplify workflows and achieve high density cultures, the Gibco™ Bacto™ CD Supreme supports advancements in therapeutics, gene therapy, and vaccine development. Discover data shared by experts and explore how you can improve process productivity and reduce risks.

Learn more about several innovative techniques that can shorten time-to-market, reduce development costs, increase yield, and assure quality and pharmacopoeia compliance throughout the drug development process.

This webinar highlights the development of the first chemically defined microbial medium. Designed to simplify workflows and achieve high density cultures, the Gibco™ Bacto™ CD Supreme supports advancements in therapeutics, gene therapy, and vaccine development. Discover data shared by experts and explore how you can improve process productivity and reduce risks.

The animal origin-free (AOF) trend in bioprocessing has taken a while to reach microbial bioproduction. In this podcast, we explore the reasons behind this and delve into how AOF products are impacting the future of biopharmaceutical manufacturing. We also discuss the first chemically defined microbial medium—the Gibco™ Bacto™ CD Supreme Fermentation Production Medium (FPM). Hydrolysate-free and AOF, this dry powder medium was specially designed to support high-cell-density cultures of E. Coli. Listen to bioprocessing experts and discover more.

Accelerate your viral vector and vaccine development with high-performance media, supplements, services, and support. Discover our extensive, cutting-edge portfolio, including Gibco™ Bacto™ CD Supreme, the first chemically defined microbial media, designed to support high cell density cultures of E. coli. Read the brochure to explore how you can optimize your workflow, while minimizing risks and improving cost effectiveness.

Despite the long-standing popularity of E. coli for microbial bioprocessing, the options for growth media have been traditionally limited. This media has often included animal origin (AO) components which can reduce batch-to-batch consistency and present safety risks to patients. Significant effort from across the industry has been focused on developing the first commercially available chemically defined microbial media. Read the article and learn how the Gibco™ Bacto™ CD Supreme Fermentation Production Media is helping to manufacture the next generation of biopharmaceuticals.

The cell and gene therapeutic market is growing substantially and finding a way to increase manufacturing capacity while maintaining high-quality standards poses a unique challenge. With a focus on maintaining consistency, utilizing a fully chemically defined medium, such as Gibco™ Bacto™ CD Supreme, can help to mitigate variability risks. Read the whitepaper to explore scalable process workflow solutions available from initial R&D investment to clinical testing, and commercialization.

Automated method development and robustness workflow for Triumeq and related compounds using ChromSwordAuto and Thermo Scientific Vanquish Core HPLC

Improve process productivity and performance with the state-of-the-art Gibco™ Efficient‑Pro™ Medium and feed system. Formulated to work in perfect harmony, the system comprises the high-performance Efficient-Pro Medium and a choice of two premium feeds—Gibco™ Efficient-Pro™ Feed 1 for CHO-K1 cells and Gibco™ Efficient-Pro™ Feed 2 for CHO-S, CHO-GS, and CHO-DG44 cells. Watch our how-to video to learn how the system can help simplify your process and elevate your monoclonal antibody (mAb) quality and titers. Utilize our specialized insights to develop your optimal Efficient‑Pro feeding protocol and maximize the benefits of choosing the Efficient-Pro™ system. Revolutionize your process with a cutting-edge media and feed system, designed to accelerate your mAb manufacturing workflow and transform your process performance.

Learn how Gibco™ Rapid Prototyping can help idenitfy the most feasible cell culture media for cGMP scale-up.

This session will address ways to help streamline media manufacturing, including rapid, small-scale non-cGMP media prototyping and proprietary media formulation outsourcing options.

Learn how Gibco™ Rapid Prototyping can accelerate your journey to cGMP

This application note demonstrates a streamlined HPLC method scouting workflow for the analysis of esomeprazole and related degradation products.

Therapeutic proteins have been explored for their use in cancer treatment, autoimmune disease, and other difficult-to-treat conditions. But, their stability is critical for patient safety and efficacy. This ebook on FTIR/NIR/Raman in Bio/Pharmaceutical Analysis discusses some common techniques used for evaluated the physical stability and activity of biologics.

This tech note evaluates intra- and inter-system retention time and peak area precision for the analysis of two active pharmaceutical ingredients and their related impurities

This application note demonstrates how to develop a single method with direct detection of choline salts and impurities without the need for derivatization.

This whitepaper reveals strategies that create simple, stable formulations for your sterile injectable, a solid foundation for the entire life cycle of your product.

This whitepaper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.

Separation of 15 nitrosamines was achieved in under 14 minutes with LOQs <2 ng/g (ppb w/w) validated to ICH regulatory guidelines and easily meeting FDA LOQ requirements of 30 ppb.

*Wednesday, May 19, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST* Listen and learn as Alexander Schwenger from CureVac and Frank Steiner from Thermo Fisher Scientific discuss the highlights of 2-dimensional LC and innovative use cases and discuss current and future challenges in in vaccine research, development, and production. *Available On Demand May 19, 2022*

To bring lifesaving cell and gene therapies to the market, an efficient and scalable manufacturing strategy is needed. Find out more in this whitepaper.

Download this whitepaper to get a better understanding of the evolving regulatory guidelines for cell and gene therapies, in order to bring them to market faster.